Financial Performance - Total revenue for Q3 2025 was $553 million, a 4% increase year-over-year[6] - Net income for Q3 2025 was $53 million, or $0.43 diluted EPS, representing a 38% increase from $39 million in Q3 2024[8] - Non-GAAP net income for Q3 2025 was $80 million, or $0.65 diluted EPS, a 10% increase from $72 million in Q3 2024[8] - Adjusted EBITDA for Q3 2025 was $123 million, or 22.2% of revenue, compared to $122 million in Q3 2024[8] - Total costs and expenses for Q3 2025 were $483 million, a 4% increase year-over-year[10] - Adjusted EBITDA for the fiscal year was $339 million, with Q3 contributing $122 million[40] - Non-GAAP net income for the fiscal year reached $188 million, with Q3 showing $72 million[40] - GAAP total revenue growth was 4% for the fiscal year, while non-GAAP total revenue growth on a constant currency basis was also 3%[40] - GAAP net income (loss) for Q3 was $53 million, compared to a loss of $11 million in Q2[40] Revenue Breakdown - Viator revenue for Q3 2025 was $294 million, reflecting a 9% year-over-year growth[14] - TheFork revenue for Q3 2025 was $63 million, a 28% year-over-year increase[14] - The total revenue growth for the Viator segment was 14% for the fiscal year, with constant currency growth at 14%[40] - TheFork segment revenue growth was 18% for the fiscal year, with constant currency growth at 19%[40] - Tripadvisor-branded hotels generated $948.8 million in revenue for FY 2024, with a year-over-year decline of 8%[42] - Viator's revenue increased by 14% year-over-year to $840.1 million in FY 2024[42] - TheFork's revenue for FY 2024 was $180.8 million, with a year-over-year growth of 18%[42] Assets and Liabilities - Total assets increased to $2,845 million as of September 30, 2025, up from $2,561 million on December 31, 2024, representing a growth of 11.1%[20] - Total current liabilities rose to $1,150 million as of September 30, 2025, compared to $628 million on December 31, 2024, marking a significant increase of 83.1%[20] - Long-term debt stood at $821 million as of September 30, 2025, slightly down from $831 million on December 31, 2024[20] - Stockholders' equity decreased to $707 million as of September 30, 2025, from $943 million at the end of 2024, a decline of 25.0%[20] Cash Flow and Expenditures - Cash and cash equivalents at the end of the period were $1,218 million, up from $1,064 million at the beginning of the period, indicating a net increase of $154 million[22] - The company reported a net cash provided by operating activities of $45 million for the three months ended September 30, 2025, compared to a net cash used of $44 million in the same period of 2024[22] - The company incurred capital expenditures of $19 million for the three months ended September 30, 2025, compared to $20 million in the same period of 2024[22] - Capital expenditures for the fiscal year amounted to $74 million, with Q3 at $20 million[40] Operational Metrics - The number of experience bookings on Viator increased by approximately 18% year-over-year to about 6.6 million[14] - Gross bookings value (GBV) reached $1.3 billion in Q3 2025, reflecting a year-over-year growth of approximately 15%[14] - The company continues to focus on operational metrics such as Gross Booking Value (GBV) to assess marketplace health and engagement[51] Strategic Initiatives - The company expects at least $85 million in annualized gross cost savings, fully realized by 2027[4] - Forward-looking statements regarding Tripadvisor's future financial performance and strategic initiatives involve known and unknown risks and uncertainties[56] - Tripadvisor aims to be the world's most trusted source for travel and experiences, leveraging its brands and technology[57] Other Financial Insights - Stock-based compensation expense totaled $120 million for the fiscal year, with Q3 accounting for $29 million[40] - The estimated effects of foreign currency exchange rates on revenue indicated a 1% impact on total revenue growth for Q3[40] - The company reported a decline in Adjusted EBITDA growth rates across segments, with the Brand segment down 23% year-over-year[49] - Tripadvisor's unique user metrics may not accurately reflect the actual number of users due to multiple accounts and device usage[54] - Consolidated Adjusted EBITDA is a non-GAAP measure, excluding certain operating expenses, and is defined in relation to GAAP measures[55]

Exhibit 99.1 Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Timelines Reiterated for Top Line Clinical Results from Ongoing Trials of Investigational Anti- TSLP Monoclonal Antibody Bosakitug (ATI-045) and Anti-TSLP/IL-4R Bispecific Antibody ATI- 052 - Pipeline: Oral Inhibitors: ITK Franchise ● Announced Anticipated Phase 2 Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3, in an Additional Indication: Aclaris expects to fur ...

Revenue and Sales Performance - Third quarter 2025 revenue increased by 21% to $24.4 million compared to $20.2 million in the third quarter of 2024[6] - Net sales for the three months ended September 30, 2025, increased to $24,411 million, up 21.5% from $20,179 million in the same period last year[26] Profitability and Earnings - Net income for Q3 2025 rose 46% to $3.4 million, or $0.87 per diluted share, compared to $2.4 million, or $0.63 per diluted share, in Q3 2024[8] - Non-GAAP adjusted earnings for Q3 2025 were $5.0 million, or $1.27 per diluted share, compared to $2.7 million, or $0.71 per diluted share, in Q3 2024[9] - Operating income for Q3 2025 was $4.8 million, compared to $2.6 million in Q3 2024[8] - Basic earnings per share for the three months ended September 30, 2025, were $0.93, compared to $0.67 for the same period in 2024, an increase of 38.8%[26] Margins and EBITDA - Gross margin for Q3 2025 was 49.9%, up from 38.8% in Q3 2024, primarily due to the product mix with the BKR 9000 gaining traction[6] - Non-GAAP adjusted EBITDA for Q3 2025 was $5.3 million, compared to $3.1 million in Q3 2024[10] - Adjusted EBITDA for the three months ended September 30, 2025, was $5,252 million, up from $3,109 million in the same period last year, reflecting a 68.9% increase[30] Cash and Working Capital - The company ended Q3 2025 with a record cash balance of $21.5 million and no debt[5] - Working capital at September 30, 2025, was approximately $33.8 million, compared to $23.0 million at December 31, 2024[10] - Cash and cash equivalents as of September 30, 2025, were $21,471 million, significantly higher than $7,075 million at the end of 2024, indicating a 202.5% increase[28] Assets and Liabilities - Total current assets as of September 30, 2025, increased to $51,748 million, compared to $36,941 million as of December 31, 2024, marking a growth of 39.9%[28] - Total liabilities as of September 30, 2025, were $25,914 million, up from $21,668 million as of December 31, 2024, representing a 19.5% increase[28] Guidance and Future Outlook - For the full year 2025, the company is reiterating guidance of high single-digit revenue growth, gross margin of 47%+, GAAP EPS of $3.15, and non-GAAP adjusted EPS of $3.80[3] Development Costs and Shares - The company reported a significant increase in capitalized product development costs, rising to $2,837 million as of September 30, 2025, from $1,321 million at the end of 2024[28] - The weighted average common shares outstanding, basic, increased to 3,708,717 for the three months ended September 30, 2025, compared to 3,539,841 in the same period last year[30] Expenses - Selling, General & Administrative expenses for Q3 2025 totaled $7.3 million, up from $5.2 million in Q3 2024[7]

Revenue Growth - Total revenues increased by approximately 11% to $45,687,000 for the thirteen weeks ended September 28, 2025, compared to $41,109,000 for the same period in 2024[116] - Total revenues increased by approximately 8% to $92,685,000 for the twenty-six weeks ended September 28, 2025, compared to $85,876,000 for the same period in fiscal 2025[140] - Foodservice sales from the Branded Product Program increased by approximately 18% to $29,047,000 for the second quarter fiscal 2026, compared to $24,536,000 for the second quarter fiscal 2025[117] - Foodservice sales from the Branded Product Program increased by approximately 15% to $58,122,000 for the fiscal 2026 period compared to $50,682,000 for fiscal 2025[141] Sales Performance - The total volume of hot dogs sold in the Branded Product Program increased by approximately 7% compared to the second quarter fiscal 2025, with an average selling price increase of approximately 11%[117] - Total Company-owned restaurant sales increased by approximately 5% to $5,624,000 during the second quarter fiscal 2026, compared to $5,348,000 during the same period in 2025[118] - Comparable domestic franchise sales were $28,957,000 in fiscal 2026 compared to $29,379,000 in fiscal 2025, reflecting a decline in sales[144] - Franchise fees and royalties increased by approximately 4% to $1,223,000 in Q2 fiscal 2026 compared to $1,174,000 in Q2 fiscal 2025, with franchise restaurant sales increasing to $19,873,000 from $18,681,000[120] Cost and Expenses - Overall cost of sales increased by approximately 24% to $32,378,000 in Q2 fiscal 2026 compared to $26,029,000 in Q2 fiscal 2025, resulting in a gross profit of $2,293,000 or 7%[123] - General and administrative expenses increased by $200,000 or 6% to $3,452,000 in Q2 fiscal 2026 compared to $3,252,000 in Q2 fiscal 2025[127] - Cost of sales rose by approximately 19% to $60,801,000 in fiscal 2026 compared to $51,270,000 in fiscal 2025, with gross profit decreasing to $6,931,000 (10%) from $8,959,000 (15%)[147] - The cost of sales in the Branded Product Program increased by 21% to $55,823,000 due to a 3% increase in hot dog sales volume and a 16% rise in average cost per pound[148] Profitability - EBITDA for the thirteen weeks ended September 28, 2025, was $7,996,000, compared to $9,787,000 for the same period in 2024[113] - Adjusted EBITDA for the thirteen weeks ended September 28, 2025, was $8,280,000, compared to $10,350,000 for the same period in 2024[113] - The average cost of hot dogs during fiscal 2026 was approximately 16% higher than in fiscal 2025, indicating inflationary pressures on commodity prices[185] Cash Flow and Dividends - Cash and cash equivalents increased by $4,373,000 to $32,175,000 as of September 28, 2025, compared to $27,802,000 at March 30, 2025[163] - Net cash provided by operating activities was $9,938,000 in fiscal 2026, down from $14,826,000 in fiscal 2025[166] - The company paid cash dividends totaling $4,089,000 during fiscal 2026, with a declared third-quarter dividend of $0.50 per share and a special cash dividend of $2.50 per share[177] - The Company's total cash requirement for dividends for fiscal 2026 is approximately $18,403,000, including a special cash dividend of $2.50 per share[178] Interest and Tax - Interest expense decreased by $702,000 to $739,000 in Q2 fiscal 2026 due to lower outstanding long-term debt and a lower interest rate associated with the Credit Agreement[131] - Interest expense decreased to $1,497,000 in fiscal 2026 from $2,501,000 in fiscal 2025, primarily due to lower outstanding long-term debt[153] - The effective income tax rate for fiscal 2026 was 26.7%, comparable to the previous fiscal year, reflecting an income tax expense of $5,151,000 on pre-tax income of $19,278,000[157] Market Conditions and Risks - Nathan's Famous anticipates continued inflationary pressures on commodity prices, including beef and labor, during the remainder of fiscal 2026[105] - The Company's future operating results could be impacted by supply constraints on beef or increased costs due to inflationary pressures[104] - A hypothetical 100 bps increase in interest rates on $49,600,000 of outstanding Term Loan borrowings would increase cash interest costs by approximately $496,000 over the next twelve months[192] - Inflationary pressures on labor and rising commodity prices have significantly impacted financial results, particularly in New York State due to minimum wage increases[186] - The Company expects to continue experiencing volatility in oil and gas prices affecting distribution and utility costs[194] - The Company has not hedged against fluctuations in commodity prices, exposing it to market changes in future purchases[195]

Product Approval and Clinical Development - KIMMTRAK, the lead product, is approved in 39 countries and has been commercially launched in 28 countries, including the U.S., Germany, and France[74] - The Independent Data Monitoring Committee recommended a dose of 160 mcg for the ongoing Phase 3 trial in advanced cutaneous melanoma[80] - The company has treated over 2,000 cancer patients with KIMMTRAK and other ImmTAX product candidates, representing a significant clinical data set[75] - The company entered into a clinical trial collaboration with Bristol-Myers Squibb to investigate the ImmTAC bispecific TCR candidate brenetafusp in combination with nivolumab for advanced cutaneous melanoma, sponsoring a Phase 3 trial without monetary consideration[146] Financial Performance - Revenue from the sale of therapies, net for Q3 2025 was $103.7 million, representing a 29.2% increase from $80.2 million in Q3 2024[101] - For the three months ended September 30, 2025, the company generated net revenue from the sale of therapies of $103.7 million, a 29.2% increase from $80.2 million in the same period of 2024[102] - Revenue from the sale of therapies in the United States was $67.3 million, representing a 17.5% increase, while Europe saw a significant increase of 58.9% to $33.5 million[102] - For the nine months ended September 30, 2025, total revenue was $295.5 million, a 30.8% increase from $225.9 million in the same period of 2024[111] - The company reported a foreign currency gain of $3.7 million for the nine months ended September 30, 2025, compared to $1.0 million in the same period of 2024[120] Operating Losses and Financial Position - The company incurred net losses of $0.2 million and $5.5 million for the three and nine months ended September 30, 2025, respectively, with an accumulated deficit of $801.2 million as of the same date[77] - The company expects to continue incurring significant operating losses as it advances product candidates through clinical development and seeks regulatory approvals[77] - The company has an accumulated deficit of $801.2 million as of September 30, 2025, indicating ongoing operating losses[123] - The company expects to incur significant operating losses in the foreseeable future as it continues to commercialize KIMMTRAK and advance its product candidates through clinical development[132] Research and Development Expenses - R&D expenses are anticipated to increase as the company advances existing and future product candidates into clinical studies[87] - Total R&D expenses for the three months ended September 30, 2025, were $70.6 million, up 33.7% from $52.8 million in the same period of 2024[103] - Total R&D expenses for the nine months ended September 30, 2025, were $196.0 million, a 21.5% increase from $161.3 million in the same period of 2024[115] - External R&D expenses increased by $16.1 million, primarily due to a $9.2 million rise in costs related to clinical and preclinical programs[104] Cash and Liquidity - As of September 30, 2025, the company had cash and cash equivalents of $498.4 million, an increase from $455.7 million as of December 31, 2024, and marketable securities of $393.9 million, up from $364.6 million[128] - Cash and cash equivalents increased to $498.4 million as of September 30, 2025, up from $455.7 million as of December 31, 2024[161] - The company anticipates that existing cash and cash equivalents, along with expected revenue from KIMMTRAK, will fund operating expenses for at least twelve months from the filing date of the Quarterly Report[134] - Net cash provided by operating activities was $21.9 million for the nine months ended September 30, 2025, a decrease of $18.1 million compared to $40.0 million for the same period in 2024[129] - Net cash used in investing activities was $15.5 million for the nine months ended September 30, 2025, significantly lower than $351.6 million for the same period in 2024, primarily due to reduced purchases of marketable securities[130] Tax and Regulatory Considerations - As of September 30, 2025, accumulated tax losses available for carry forward in the U.K. were $275.7 million[98] - The company may benefit from the U.K.'s "patent box" regime, allowing profits from patented products to be taxed at a lower rate of 10%[99] - The U.K. R&D tax credit regime allows for cash rebates of up to 15% on qualifying R&D expenses incurred after April 1, 2023[89] Financial Risks and Obligations - The company has material contractual lease obligations that could result in payments of up to $75.7 million, primarily for significant facilities in the UK[141] - The company has existing manufacturing obligations related to KIMMTRAK that could result in payments of up to $20.1 million, expected to increase as the pipeline advances in 2025 and beyond[142] - The company may need to raise additional funds through public or private equity offerings, debt financing, or collaborations to support long-term clinical development[138] - The company is exposed to credit risk primarily from accounts receivable and cash equivalents, but the exposure to credit losses is low due to the credit quality of its distributors[163] - The financial risk committee oversees the management of interest rate, currency, credit, and liquidity risks, ensuring compliance with appropriate policies[156] Revenue Deductions and Impact - As of September 30, 2025, total accrued revenue deductions were $170.2 million, with $10.2 million subject to greater estimation uncertainty[153] - The company expects to pay approximately $65.0 million related to accrued revenue deductions in the three months ending December 31, 2025[153] - A 20% change in expected rebate and chargeback percentages could result in a $2.0 million impact on net revenue from therapy sales for the nine months ended September 30, 2025[154] Currency and Exchange Rate Risks - As of September 30, 2025, 75% of cash and cash equivalents were held by the U.K. operating subsidiary, with 48% in U.S. dollars, 39% in pounds sterling, and 13% in euros[161] - A five percentage point increase in exchange rates would reduce the carrying value of net financial assets and liabilities held in foreign currencies by $5.9 million as of September 30, 2025[162]

NEWS RELEASE Exhibit 99.1 Earnings Guidance The Company narrows its 2025 adjusted EPS (non-GAAP) guidance range of $3.92 to $4.02 from its original 2025 adjusted EPS (non-GAAP) guidance range of $3.92 to $4.12. Additionally, the Company reaffirms its long-term adjusted EPS (non-GAAP) annual growth target of 4% to 6% through 2029 based on the 2025 adjusted EPS (non-GAAP) guidance midpoint of $4.02. The Company expects adjusted EPS growth in the upper half of the 4% to 6% range beginning in 2026. Adjusted EPS ...

Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2025 Financial Results HOLLISTON, Mass., November 6, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2025. "Our third-quarter performance highlights our growth opportunity while we advance efforts to fortify our capital structure. We saw another uptick in our performance on a sequential basis as our focus on executing, accelerati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 1-14287 Centrus Energy Corp. ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Delaware 52-2107911 (State of incorporation) (I.R.S. Employer Identification No.) 6901 Rockledge Drive, Suite 800, Bethesda, Maryland 20817 (301 ...

Exhibit 99.1 FOR IMMEDIATE RELEASE November 6, 2025 Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the third quarter ended September 28, 2025. Third quarter financial summary 2025 guidance summary "We executed well in the third quarter, delivering adjusted operating margin and earnings per share above our expectations and revenue at the midpoint of our guidance range, despite low ...

Exhibit 99.1 AAON Reports Strong Third Quarter 2025 Results Driven by Operational Improvements and Share Gains Q3 Highlights (All comparisons are year-over-year, unless otherwise noted) TULSA, Okla., November 6, 2025 - AAON, INC. (NASDAQ-AAON), a leader in high-performing, energy-efficient HVAC solutions that bring long-term value to customers and owners, today announced its results for the third quarter of 2025. The quarter demonstrated robust underlying demand across both AAON and BASX brands. Total backl ...